Trials / Withdrawn
WithdrawnNCT03048136
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
A Phase Ib/II Safety Trial of Nivolumab in Combination With Ipilimumab Administered in Participants With Chemotherapy-naive Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (CheckMate 955: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 955)
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
Detailed description
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Specified dose on specified days |
| DRUG | Ipilimumab | Specified dose on specified days |
Timeline
- Start date
- 2018-03-09
- Primary completion
- 2019-09-29
- Completion
- 2019-09-29
- First posted
- 2017-02-09
- Last updated
- 2018-04-17
Locations
17 sites across 5 countries: United States, Argentina, Canada, Germany, Peru
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03048136. Inclusion in this directory is not an endorsement.